ECL:NYSEEcolab Inc. Analysis
Data as of 2026-03-30 - not real-time
$264.75
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Ecolab (ECL) is trading at $264.75, roughly 21% above its DCF‑derived fair value of $141. The stock sits just above its 20‑day SMA of $273.18 and below the 50‑day SMA of $284.89, indicating a modest near‑term pullback. Momentum metrics are mixed: the RSI of 37.8 points to mild oversold conditions, while the MACD remains in a bearish crossover. Support at $252.66 provides a cushion, but the next resistance near $299.88 is still a distance away. On the fundamentals side, revenue grew 17.8% year‑over‑year and EPS is expected to rise to $9.69 forward, reflecting solid top‑line expansion. Recent strategic acquisitions—including the Ovivo water‑solutions deal and the $4.75 B CoolIT Systems purchase—are aimed at strengthening high‑tech water and digital platforms.
The company generates $1.64 B of free cash flow and pays a 1.06% dividend with a modest 36.8% payout ratio, suggesting dividend sustainability. However, a debt‑to‑equity ratio of 104% and a beta near 0.6 signal modest financial leverage and lower market sensitivity. Volatility over the past 30 days sits at 22%, which is higher than the broader market but manageable given the stock’s liquidity. Analysts have upgraded ECL to Buy with a median price target of $326, implying further upside despite the current overvaluation. Given the blend of growth catalysts and a valuation premium, the stock appears overvalued in the short run but offers a compelling growth‑oriented profile. Our recommendation is to hold for the near term, accumulate on dips, and consider a longer‑term position if the acquisitions deliver the projected margin expansion.
The company generates $1.64 B of free cash flow and pays a 1.06% dividend with a modest 36.8% payout ratio, suggesting dividend sustainability. However, a debt‑to‑equity ratio of 104% and a beta near 0.6 signal modest financial leverage and lower market sensitivity. Volatility over the past 30 days sits at 22%, which is higher than the broader market but manageable given the stock’s liquidity. Analysts have upgraded ECL to Buy with a median price target of $326, implying further upside despite the current overvaluation. Given the blend of growth catalysts and a valuation premium, the stock appears overvalued in the short run but offers a compelling growth‑oriented profile. Our recommendation is to hold for the near term, accumulate on dips, and consider a longer‑term position if the acquisitions deliver the projected margin expansion.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and modest upside versus fair value
- Support level near $252.66 provides downside protection
- Recent acquisitions still pending integration
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Revenue growth and EPS expansion outlook
- Strategic acquisitions targeting high‑margin water solutions
- Improving free cash flow and sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong franchise and recurring revenue streams
- Dividend sustainability and strong cash generation
- Long‑term secular demand for water and hygiene solutions
Key Metrics & Analysis
Financial Health
Revenue Growth17.80%
Profit Margin12.91%
P/E Ratio36.3
ROE22.52%
ROA7.84%
Debt/Equity103.92
P/B Ratio11.3
Op. Cash Flow$3.0B
Free Cash Flow$1.6B
Technical Analysis
TrendNeutral
RSI37.8
Support$252.66
Resistance$299.88
MA 20$273.18
MA 50$284.89
MA 200$272.82
MACDBearish
VolumeStable
Fear & Greed Index67.7
Valuation
Fair Value$141.23
Target Price$320.43
Upside/Downside21.03%
GradeOvervalued
TypeGrowth
Dividend Yield1.06%
Risk Assessment
Beta0.58
Volatility22.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.